TWI882058B - 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法 - Google Patents

以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法 Download PDF

Info

Publication number
TWI882058B
TWI882058B TW110100632A TW110100632A TWI882058B TW I882058 B TWI882058 B TW I882058B TW 110100632 A TW110100632 A TW 110100632A TW 110100632 A TW110100632 A TW 110100632A TW I882058 B TWI882058 B TW I882058B
Authority
TW
Taiwan
Prior art keywords
inhibitor
dpp
individual
mace
pharmaceutically acceptable
Prior art date
Application number
TW110100632A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140019A (zh
Inventor
肯尼斯 尤金 勒碧歐達
克里斯多夫 洛斯 阿姆斯壯 哈里戴
亞茲 納伊 坎
Original Assignee
加拿大商瑞斯弗洛吉克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商瑞斯弗洛吉克斯公司 filed Critical 加拿大商瑞斯弗洛吉克斯公司
Publication of TW202140019A publication Critical patent/TW202140019A/zh
Application granted granted Critical
Publication of TWI882058B publication Critical patent/TWI882058B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Paper (AREA)
TW110100632A 2020-01-08 2021-01-07 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法 TWI882058B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958474P 2020-01-08 2020-01-08
US62/958,474 2020-01-08

Publications (2)

Publication Number Publication Date
TW202140019A TW202140019A (zh) 2021-11-01
TWI882058B true TWI882058B (zh) 2025-05-01

Family

ID=76788523

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110100632A TWI882058B (zh) 2020-01-08 2021-01-07 以bet溴結構域抑制劑及二肽基肽酶4抑制劑之組合治療及/或預防主要不良心血管事件(mace)的方法

Country Status (9)

Country Link
US (1) US20230241064A1 (cg-RX-API-DMAC10.html)
EP (1) EP4087575A4 (cg-RX-API-DMAC10.html)
JP (1) JP7763761B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220124736A (cg-RX-API-DMAC10.html)
CN (1) CN115003306A (cg-RX-API-DMAC10.html)
CA (1) CA3164933A1 (cg-RX-API-DMAC10.html)
IL (1) IL294344B2 (cg-RX-API-DMAC10.html)
TW (1) TWI882058B (cg-RX-API-DMAC10.html)
WO (1) WO2021140418A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12551484B2 (en) 2019-11-05 2026-02-17 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
AU2021368618B2 (en) 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
KR20110135411A (ko) * 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112016003584A8 (pt) * 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
KR20160043118A (ko) * 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
JP2017528431A (ja) * 2014-07-17 2017-09-28 ジェローム シェンターク, 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CN109824608B (zh) * 2019-03-15 2022-06-21 深圳晶泰科技有限公司 一种Apabetalone晶型及其制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
期刊 Karagiannis et al. Cardiovascular risk with DPP-4 inhibitors: Latest evidence and clinical implications Therapeutic Advances in Drug Safety 7(2) 2016 36-38
期刊 Liu et al. Cardiovascular risk with DPP-4 inhibitors: Latest evidence and clinical implications BMC Pharmacology and Toxicology 20 2019 15
期刊 Nicholls et al. Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial American Journal of Cardiovascular Drugs 16 2016 55-65
期刊 Packer et al. Cardiovascular risk with DPP-4 inhibitors: Latest evidence and clinical implications Circulation Research 122(7) 2018 928-932
網路文獻 Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - BETonMACE AMERICAN COLLEGE of CARDIOLOGY 2019.11.16 https://www.acc.org/latest-in-cardiology/clinical-trials/2019/11/15/17/25/betonmace

Also Published As

Publication number Publication date
KR20220124736A (ko) 2022-09-14
US20230241064A1 (en) 2023-08-03
JP7763761B2 (ja) 2025-11-04
IL294344B2 (en) 2026-07-01
CA3164933A1 (en) 2021-07-15
EP4087575A1 (en) 2022-11-16
EP4087575A4 (en) 2024-02-28
IL294344B1 (en) 2026-03-01
WO2021140418A1 (en) 2021-07-15
TW202140019A (zh) 2021-11-01
IL294344A (en) 2022-08-01
CN115003306A (zh) 2022-09-02
JP2023509186A (ja) 2023-03-07

Similar Documents

Publication Publication Date Title
TWI867086B (zh) 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法
CA2851996C (en) Pharmaceutical compositions for substituted quinazolinones
JP7763761B2 (ja) Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法
TW202233194A (zh) 以bet溴結構域抑制劑及鈉依賴型葡萄糖轉運2抑制劑之組合於改善腎功能之方法
US20120309779A1 (en) Methods and compositions comprising sequential administration of opioid receptor agonists
US20230398137A1 (en) Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US9084769B2 (en) Compositions comprising non steroidal anti-inflammatory drugs and methods for use thereof
HK40081394A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
HK40081394B (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
EA047426B1 (ru) Способы лечения и/или предотвращения серьезных нежелательных сердечно-сосудистых явлений (снсся) с помощью комбинации ингибитора бромодомена bet и ингибитора натрий-глюкозного котранспортера 2-го типа
EA049336B1 (ru) Способы улучшения функции почек при помощи комбинации ингибитора бромодомена bet и ингибитора натрий-зависимого транспортера глюкозы 2 типа